Search
Ubrogepant
go.drugbank.com/drugs/DB15328ApprovedInvestigationalUbrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. … [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesDasiglucagon
go.drugbank.com/drugs/DB15226Approved[L39200] Treatments for severe hypoglycemia have mostly been limited to intravenous dextrose and different glucagon formulations. … [L39190] It consists of 29 amino acids similar to endogenous glucagon; however, it contains seven substituted amino acids for improved physical and chemical stability in its drug formulation.
Valine
go.drugbank.com/drugs/DB00161ApprovedInvestigationalNutraceuticalValine is a branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.
Mixtures: GLAMIN SOLUTION FOR INFUSION, KABIVEN EMULSION FOR INFUSIONMagnesium carbonate
go.drugbank.com/drugs/DB09481ApprovedMagnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label].
Categories: Drugs for Constipation, Drugs for Acid Related DisordersSulfapyridine
go.drugbank.com/drugs/DB00891ApprovedWithdrawnAntibacterial, potentially toxic, and previously used to treat certain skin diseases. No longer prescribed.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseCefotiam
go.drugbank.com/drugs/DB00229ApprovedOne of the cephalosporins that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseMitapivat
go.drugbank.com/drugs/DB16236ApprovedInvestigational[A245478] On January 5, 2026, the FDA also approved the use of in the treatment of anemia in adults with alpha- or beta-thalassemia, making it the first oral treatment for this condition.[L54953] … Defects in the pyruvate kinase enzyme in various red blood cells disorders lead to the lack of energy production for red blood cells, leading to lifelong premature destruction of red blood cells or chronic
Dapagliflozin
go.drugbank.com/drugs/DB06292ApprovedInvestigationalDapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. … [L48251] It was later approved to reduce the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease in April
Celiprolol
go.drugbank.com/drugs/DB04846ApprovedInvestigationalWithdrawnCeliprolol is not approved for use by the FDA in the treatment of vascular Ehlers–Danlos syndrome. … Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris.
Cefixime
go.drugbank.com/drugs/DB00671ApprovedInvestigational[A263026] However, cefixime is not recommended as a first-line of treatment for uncomplicated urogenital, anorectal, or pharyngeal gonorrhea because cefixime does not provide the same bactericidal effect … [A262995,A262945,A262950] Specifically, cephalosporins inhibit penicillin-sensitive enzymes responsible for the final 3D structure of the bacterial cell wall which in turn inhibit bacterial cell wall peptidoglycan
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use